Meeting of the Uniform Formulary Beneficiary Advisory Panel, 33074 [2013-13021]

Download as PDF 33074 Federal Register / Vol. 78, No. 106 / Monday, June 3, 2013 / Notices DEPARTMENT OF DEFENSE Office of the Secretary Meeting of the Uniform Formulary Beneficiary Advisory Panel Department of Defense, Assistant Secretary of Defense (Health Affairs). ACTION: Notice of meeting. AGENCY: Under the provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C. Appendix, as amended) and the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the Department of Defense (DoD) announces the following Federal Advisory Committee Meeting of the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel). DATES: Thursday, June 27, 2013, from 9:00 a.m. to 1:00 p.m. ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004. FOR FURTHER INFORMATION CONTACT: CDR Joseph Lawrence, DFO, Uniform Formulary Beneficiary Advisory Panel, 4130 Stanley Road, Suite 208, Building 1000, San Antonio, TX 78234–6012. Telephone: (210) 295–1271. Fax: (210) 295–2789. Email Address: Baprequests@tma.osd.mil. SUMMARY: SUPPLEMENTARY INFORMATION: Purpose of Meeting: The Panel will review and comment on recommendations made to the Director of TRICARE Management Activity, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary. sroberts on DSK5SPTVN1PROD with NOTICES Meeting Agenda 1. Sign-In 2. Welcome and Opening Remarks 3. Public Citizen Comments 4. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item) a. Gout Agents b. Pulmonary—2 Agents: COPD c. Tobacco Cessation Agents d. Pulmonary—2 Agents e. Designated Newly Approved Drugs in Already-Reviewed Classes 1. Non-insulin Diabetes Drugs: canagliflozin (Invokana) f. Pertinent Utilization Management Issues 5. Panel Discussions and Vote Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102–3.140 through 102–3.165, and the availability of space, this meeting is open to the public. Seating is limited VerDate Mar<15>2010 16:40 May 31, 2013 Jkt 229001 and will be provided only to the first 220 people signing-in. All persons must sign-in legibly. Administrative Work Meeting: Prior to the public meeting, the Panel will conduct an Administrative Work Meeting from 7:30 a.m. to 9:00 a.m. to discuss administrative matters of the Panel. The Administrative Work Meeting will be held at the Naval Heritage Center, 701 Pennsylvania Avenue NW., Washington, DC 20004. Pursuant to 41 CFR 102–3.160, the Administrative Work Meeting will be closed to the public. Written Statements: Pursuant to 41 CFR 102–3.105(j) and 102–3.140, the public or interested organizations may submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel’s Designated Federal Officer (DFO). The DFO’s contact information can be obtained from the General Services Administration’s Federal Advisory Committee Act Database at https:// www.fido.gov/facadatabase/public.asp. Written statements that do not pertain to the scheduled meeting of the Panel may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting, then these statements must be submitted no later than 5 business days prior to the meeting in question. The DFO will review all submitted written statements and provide copies to all the committee members. Public Comments: In addition to written statements, the Panel will set aside 1 hour for individuals or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice; but if they still want to address the Panel, then they will be afforded the opportunity to register to address the Panel. The Panel’s DFO will have a ‘‘Sign-Up Roster’’ available at the Panel meeting for registration on a first-come, first-serve basis. Those wishing to address the Panel will be given no more than 5 minutes to present their comments, and at the end of the 1 hour time period, no further public comments will be accepted. Anyone who signs-up to address the Panel, but is unable to do so due to the time limitation, may submit their comments in writing; however, they must understand that their written comments may not be reviewed prior to the Panel’s deliberation. PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 To ensure timeliness of comments for the official record, the Panel encourages that individuals and interested groups consider submitting written statements instead of addressing the Panel. Dated: May 29, 2013. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2013–13021 Filed 5–31–13; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE Department of the Army Army Science Board Summer Study Session Department of the Army, DoD. Notice of open meeting. AGENCY: ACTION: Pursuant to the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended), the Sunshine in the Government Act of 1976 (U.S.C. 552b, as amended) and 41Code of the Federal Regulations (CFR 102–3. 140 through 160, the Department of the Army announces the following committee meeting: 1. Name of Committee: Army Science Board (ASB). 2. Date: Wednesday, July 17, 2013. 3. Time: 9:00 am–12:00 pm. 4. Location: Antlers Hilton, Four South Cascade, Colorado Springs, Colorado 80903–1685. 5. Purpose of Meeting: The purpose of the meeting is for Army Science Board members to review, deliberate and vote on the findings and recommendations for the FY13 Army Science Board Reports. 6. Agenda: The board will present findings and recommendations for deliberation and votes on the following four studies: Army Science and Technology Core Competencies study 2013—This study evaluates what science and technology competencies the Army must maintain and/or develop as core competencies. Evaluation of the Army’s use of Predictive Data study 2013—This study examines and evaluates the data, models and algorithms used for predictive analysis and the related potential human and ethical dimensions. Planning for Climate Change study 2013—This study considers the most likely climate change scenarios and assesses how the changes might change the way the Army fights, not just tactically but also considering all the Title 10 functions, to include manning, training and equipping. SUMMARY: E:\FR\FM\03JNN1.SGM 03JNN1

Agencies

[Federal Register Volume 78, Number 106 (Monday, June 3, 2013)]
[Notices]
[Page 33074]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-13021]



[[Page 33074]]

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Department of Defense, Assistant Secretary of Defense (Health 
Affairs).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (5 U.S.C. Appendix, as amended) and the Government in the Sunshine 
Act of 1976 (5 U.S.C. 552b, as amended) the Department of Defense (DoD) 
announces the following Federal Advisory Committee Meeting of the 
Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as 
the Panel).

DATES: Thursday, June 27, 2013, from 9:00 a.m. to 1:00 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CDR Joseph Lawrence, DFO, Uniform 
Formulary Beneficiary Advisory Panel, 4130 Stanley Road, Suite 208, 
Building 1000, San Antonio, TX 78234-6012. Telephone: (210) 295-1271. 
Fax: (210) 295-2789. Email Address: Baprequests@tma.osd.mil.

SUPPLEMENTARY INFORMATION:
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of TRICARE Management Activity, by 
the Pharmacy and Therapeutics Committee, regarding the Uniform 
Formulary.

Meeting Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Public Citizen Comments
4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Gout Agents
    b. Pulmonary--2 Agents: COPD
    c. Tobacco Cessation Agents
    d. Pulmonary--2 Agents
    e. Designated Newly Approved Drugs in Already-Reviewed Classes
    1. Non-insulin Diabetes Drugs: canagliflozin (Invokana)
    f. Pertinent Utilization Management Issues
5. Panel Discussions and Vote

    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 CFR 102-3.140 through 102-3.165, and the availability of space, this 
meeting is open to the public. Seating is limited and will be provided 
only to the first 220 people signing-in. All persons must sign-in 
legibly.
    Administrative Work Meeting: Prior to the public meeting, the Panel 
will conduct an Administrative Work Meeting from 7:30 a.m. to 9:00 a.m. 
to discuss administrative matters of the Panel. The Administrative Work 
Meeting will be held at the Naval Heritage Center, 701 Pennsylvania 
Avenue NW., Washington, DC 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140, 
the public or interested organizations may submit written statements to 
the membership of the Panel at any time or in response to the stated 
agenda of a planned meeting. Written statements should be submitted to 
the Panel's Designated Federal Officer (DFO). The DFO's contact 
information can be obtained from the General Services Administration's 
Federal Advisory Committee Act Database at https://www.fido.gov/facadatabase/public.asp. Written statements that do not pertain to the 
scheduled meeting of the Panel may be submitted at any time. However, 
if individual comments pertain to a specific topic being discussed at a 
planned meeting, then these statements must be submitted no later than 
5 business days prior to the meeting in question. The DFO will review 
all submitted written statements and provide copies to all the 
committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than 5 minutes to present their 
comments, and at the end of the 1 hour time period, no further public 
comments will be accepted. Anyone who signs-up to address the Panel, 
but is unable to do so due to the time limitation, may submit their 
comments in writing; however, they must understand that their written 
comments may not be reviewed prior to the Panel's deliberation.
    To ensure timeliness of comments for the official record, the Panel 
encourages that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: May 29, 2013.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2013-13021 Filed 5-31-13; 8:45 am]
BILLING CODE 5001-06-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.